BioMark Diagnostics, Inc.

Recent News

  • BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares

    Vancouver, British Columbia--(Newsfile Corp. - April 21, 2021) -  BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today the agreement by several long-time strategic accredited investors and insiders to exercise approximately 2,000,000 warrants issued in connection with the Company's private placement of units completed in April 2019, with the warrant exercise price of $0.20 per share. All the warrants were exercised before the warranty maturity date of April 16, 2021. The gross...

    2021-04-21 8:30 AM EDT
  • Biomark's Collaborator Receives Funding to Validate Its Biomarker Panel for the Early Detection of Lung Cancer

    Vancouver, British Columbia--(Newsfile Corp. - March 16, 2021) -  BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its sponsored research collaboration with The Metabolomics Innovation Centre (TMIC) was successful in receiving funding from the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of Health Research - Institute of Cancer Research, and Brain Canada Foundation,...

    2021-03-16 8:30 AM EDT
  • BioMark Grants Options

    Vancouver, British Columbia--(Newsfile Corp. - March 2, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that it has granted 2,100,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to third-party consultants to support market communication and corporate strategy as it advances its commercialization efforts. Each option is exercisable into one common share at a price of $0.25 per share and will vest immediately. The options will expire two...

    2021-03-02 8:30 AM EST
  • BioMark and Phytronix Technologies Inc. Enter into a Collaborative Research and Development Agreement

    Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. has entered into a collaborative research and development agreement with Phytronix Technologies Inc. ("Phytronix") to advance the development of BioMark's early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology. While BioMark Diagnostic Solutions is preparing to offer lab services and metabolomics capabilities in Quebec...

    2021-02-16 8:30 AM EST
  • BioMark Diagnostics Targets Response to Treatment Application with Its Liquid Biopsy Platform

    Vancouver, British Columbia--(Newsfile Corp. - February 8, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that the article "Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer - a Pilot Study" has been published in the peer-reviewed journal Future Science OA.Rashid A. Bux, President and CEO of BioMark, says, "This publication shows the potential of our liquid biopsy platform's ability to provide a novel and low-cost test...

    2021-02-08 8:30 AM EST
  • Alfred Berkeley Joins BioMark's Advisory Team

    Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark") is glad to announce Alfred Berkeley as a new member of the BioMark's Advisory team, as he will be providing strategic and financial advice to help expand the company's commercialization effort in the U.S.Mr. Rashid Ahmed Bux, CEO and President of BioMark Diagnostics says: "We are extremely proud and honored to have Mr. Berkeley join our advisory group at this moment....

    2021-01-11 8:30 AM EST
  • BioMark Retains Questrade, Inc. to Provide Market-Making Services

    Vancouver, British Columbia--(Newsfile Corp. - December 7, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that it has retained Questrade, Inc. ("Questrade") to provide market-making services in accordance with CSE guidelines.The term of the agreement is for one year, beginning December 7, 2020 at a cost of CAD $3,000 per month. Either party may terminate the agreement with 30 days written notice. Though BioMark and Questrade are unrelated and unaffiliated entities and Questrade will...

    2020-12-07 8:30 AM EST
  • BioMark Scientific Advisor Dr. Donald Miller to Present at the Delaware Valley Drug Metabolism Discussion Group

    Vancouver, British Columbia--(Newsfile Corp. - September 23, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that on September 29, its strategic scientific advisor Dr. Donald Miller is to present on BioMark's SSAT amantadine assay for the early detection of cancer at the prestigious Delaware Valley Drug Metabolism Discussion Group (DVDMDG).Rashid Ahmed, President and CEO of BioMark, says, "We are pleased to have Dr. Donald Miller present his important work on the...

    2020-09-23 8:30 AM EDT